More than a hundred drug candidates for stroke treatment have been tested in clinical trials [3], but mechanical thrombectomy and intravenous thrombolysis using tissue plasminogen activator (t-PA) or tenecteplase (TNK) are still the only approved medical therapies for ischemic stroke and, unfortunately, no neuroprotectant drug has ever been shown to be useful in stroke patients [4]. This evidence concerns the gene PLAT and ischemic stroke.